Comparative Pharmacology
Head-to-head clinical analysis: FAMVIR versus VITRAVENE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FAMVIR versus VITRAVENE PRESERVATIVE FREE.
FAMVIR vs VITRAVENE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Famciclovir is a prodrug that is rapidly converted to penciclovir, which inhibits viral DNA polymerase by competing with deoxyguanosine triphosphate, thereby inhibiting viral DNA synthesis and replication.
Antisense oligonucleotide that binds to mRNA of human cytomegalovirus (HCMV), inhibiting viral replication by blocking protein synthesis.
250 mg orally three times daily for 7 days for herpes zoster; 125 mg orally twice daily for 5 days for recurrent genital herpes; 250 mg orally twice daily for 7 days for first-episode genital herpes; 500 mg orally twice daily for 7 days for herpes zoster in immunocompromised patients; 500 mg orally twice daily for 7 days for recurrent mucocutaneous herpes in HIV patients.
Intravitreal injection: 330 mcg (0.05 mL of 6.6 mg/mL solution) every 2 weeks for 2 doses, then every 4 weeks.
None Documented
None Documented
Terminal elimination half-life of penciclovir is approximately 2–3 hours in patients with normal renal function; extends to 9–18 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 2 hours in patients with normal renal function. In patients with renal impairment, half-life may be prolonged up to 10 hours.
Renal: 60–70% as penciclovir via tubular secretion and glomerular filtration; fecal: <10%; biliary: <1%.
Primarily renal excretion. Approximately 40% of the dose is excreted unchanged in urine within 24 hours. Biliary/fecal excretion accounts for less than 5%.
Category C
Category C
Antiviral
Antiviral